Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05480696RecruitingPhase 2
Soluble fiber supplement for fatty liver in kids
This Phase 2 study tests whether a soluble fiber supplement can improve fatty liver disease in children who have obesity and confirmed NAFLD. It may help reduce liver fat and related liver enzyme elevations measured during clinic visits and MRI.
Hamilton, OntarioAges 8–17 - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65 - NCT05490888RecruitingPhase 1
Dose study of PHIN-214 for mild to moderate cirrhosis
This Phase 1 study tests how the medicine PHIN-214 behaves in the body and what dose is tolerable in people with Child-Pugh A or B liver cirrhosis. It may help doctors plan safer dosing for future studies.
Chandler, ArizonaAges 18–75 - NCT05499702RecruitingPhase 2
Glucagon test after dieting in type 2 diabetes
This Phase 2 study tests how glucagon affects sugar and fat handling in the liver after a short period of calorie restriction. It may help researchers understand metabolic changes in people with type 2 diabetes and guide future treatments.
Rochester, MinnesotaAges 25–65 - NCT05557448RecruitingPhase 2
N-Acetylcysteine treatment for serious acetaminophen overdose
This Phase 2 trial studies whether TYNADOTE® can treat people who have taken a harmful acetaminophen (Tylenol) overdose while checking safety. It may be considered if your overdose is high enough to put you at risk for liver injury and you can follow the treatment and follow-up visits.
Taipei, Beitou DistrictAges 20 years+ - NCT05568719RecruitingPhase 3
Testing gene therapy for hemophilia A or B
This Phase 3 trial is checking how safe and effective two gene therapies are for people with hemophilia A or hemophilia B. It only includes people who already received the study medicines through specific Pfizer studies, so it’s mainly for that existing participant group.
Rancho Cordova, CaliforniaAges 18 years+ - NCT05661786Recruiting
Study outcomes for hepatitis B with “indeterminate” disease phase
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Changzhou, JiangsuAges 18 years+ - NCT05686759RecruitingPhase 3
Tested IV Hepabig in liver-transplant patients with hepatitis B
This Phase 3 study checks whether an undiluted IV infusion of I.V.-Hepabig inj is safe and works to help prevent hepatitis B from coming back after a liver transplant. It is mainly for adults who had a hepatitis B–related liver transplant and already received Hepabig regularly.
Goyang-si, Gyeonggi-doAges 18–64 - NCT05726747Recruiting
Quality-of-life study for fluid buildup and muscle loss
This trial studies people with recurring fluid buildup in the belly (ascites) and looks at how treatments or supportive care affect quality of life and muscle strength. It may help researchers better understand which approaches improve day-to-day well-being when ascites keeps coming back.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05743868Recruiting
Study of how insulin resistance affects blood fats
This study looks at how differences in insulin resistance may change how the liver makes triglycerides (a type of blood fat). It may help researchers understand why some people have higher triglycerides and how to target them better.
AmsterdamAges 18–65 - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT05793203Recruiting
Tests noninvasive checks to spot liver transplant complications early
This study looks at how well noninvasive tests (tests that don’t require surgery or taking tissue) can detect complications after a liver transplant. It may help patients and teams find problems earlier using safer, easier monitoring.
RomeAges 18–75 - NCT05853718RecruitingPhase 4
Tenofovir treatment for hepatitis B during pregnancy
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hangzhou, ZhejiangAges 20–40 - NCT05884723Recruiting
Ketogenic diet before liver surgery for fatty liver
This trial tests whether a ketogenic (very low-carb) diet before liver surgery can reduce fat in the liver. It is aimed at people with colorectal liver metastases who already have fatty liver seen on scans or biopsy.
London, OntarioAges 18 years+ - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT05911620Recruiting
MRI test to measure liver scar severity in Cushing’s
This study uses a special MRI scan to measure how severe liver scarring is. It focuses on people with Cushing’s syndrome or suspected Cushing’s, or those with metabolic syndrome, to see how well the scan helps diagnose and assess severity.
NancyAges 18 years+ - NCT05934409Recruiting
Measuring body-fat storage after bariatric surgery
This study looks at how body fat is stored and how that may relate to early improvements in diabetes and heart/liver health after bariatric surgery. It may help researchers understand why some people recover faster and which body changes matter.
Sherbrooke, QuebecAges 18–65 - NCT05936073Recruiting
Study of patient data for people with HDV infection
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
LimogesAges 18 years+ - NCT05937178Recruiting
Real-World Study to Optimize Hepatitis B Tablet Treatment
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hefei, AnhuiAges 18–80 - NCT05968573Recruiting
Health messages intervention for people at risk of HIV or HCV
This study tests whether persuasive, health-message coaching can help people reduce risk for HIV or hepatitis C (HCV). You may be eligible if you’re not infected with HIV or HCV and haven’t been tested for either in the last year.
New York, New YorkAges 18 years+ - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT06047093Recruiting
Study of Hepatitis B Virus in the Liver
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
LyonAges 18 years+ - NCT06119997Recruiting
Liver fibrosis screening using simple blood tests in primary care
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
GrenobleAges 18–70
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 484 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.